243 related articles for article (PubMed ID: 17504997)
1. Intradermal CpG-B activates both plasmacytoid and myeloid dendritic cells in the sentinel lymph node of melanoma patients.
Molenkamp BG; van Leeuwen PA; Meijer S; Sluijter BJ; Wijnands PG; Baars A; van den Eertwegh AJ; Scheper RJ; de Gruijl TD
Clin Cancer Res; 2007 May; 13(10):2961-9. PubMed ID: 17504997
[TBL] [Abstract][Full Text] [Related]
2. Local administration of PF-3512676 CpG-B instigates tumor-specific CD8+ T-cell reactivity in melanoma patients.
Molenkamp BG; Sluijter BJ; van Leeuwen PA; Santegoets SJ; Meijer S; Wijnands PG; Haanen JB; van den Eertwegh AJ; Scheper RJ; de Gruijl TD
Clin Cancer Res; 2008 Jul; 14(14):4532-42. PubMed ID: 18628468
[TBL] [Abstract][Full Text] [Related]
3. Tumor-specific CD8+ T cell reactivity in the sentinel lymph node of GM-CSF-treated stage I melanoma patients is associated with high myeloid dendritic cell content.
Vuylsteke RJ; Molenkamp BG; van Leeuwen PA; Meijer S; Wijnands PG; Haanen JB; Scheper RJ; de Gruijl TD
Clin Cancer Res; 2006 May; 12(9):2826-33. PubMed ID: 16675577
[TBL] [Abstract][Full Text] [Related]
4. Local delivery of CpG-B and GM-CSF induces concerted activation of effector and regulatory T cells in the human melanoma sentinel lymph node.
van den Hout MF; Sluijter BJ; Santegoets SJ; van Leeuwen PA; van den Tol MP; van den Eertwegh AJ; Scheper RJ; de Gruijl TD
Cancer Immunol Immunother; 2016 Apr; 65(4):405-15. PubMed ID: 26935057
[TBL] [Abstract][Full Text] [Related]
5. Local administration of granulocyte/macrophage colony-stimulating factor increases the number and activation state of dendritic cells in the sentinel lymph node of early-stage melanoma.
Vuylsteke RJ; Molenkamp BG; Gietema HA; van Leeuwen PA; Wijnands PG; Vos W; van Diest PJ; Scheper RJ; Meijer S; de Gruijl TD
Cancer Res; 2004 Nov; 64(22):8456-60. PubMed ID: 15548718
[TBL] [Abstract][Full Text] [Related]
6. Plasmacytoid dendritic cells represent a major dendritic cell subset in sentinel lymph nodes of melanoma patients and accumulate in metastatic nodes.
Gerlini G; Urso C; Mariotti G; Di Gennaro P; Palli D; Brandani P; Salvadori A; Pimpinelli N; Reali UM; Borgognoni L
Clin Immunol; 2007 Nov; 125(2):184-93. PubMed ID: 17827069
[TBL] [Abstract][Full Text] [Related]
7. T cell infiltration on local CpG-B delivery in early-stage melanoma is predominantly related to CLEC9A
Koster BD; López González M; van den Hout MF; Turksma AW; Sluijter BJ; Molenkamp BG; van Leeuwen PA; Vosslamber S; Scheper RJ; van den Eertwegh AJ; van den Tol MP; Jordanova EJ; de Gruijl TD
J Immunother Cancer; 2021 Mar; 9(3):. PubMed ID: 33737341
[TBL] [Abstract][Full Text] [Related]
8. Effects of the administration of high-dose interleukin-2 on immunoregulatory cell subsets in patients with advanced melanoma and renal cell cancer.
van der Vliet HJ; Koon HB; Yue SC; Uzunparmak B; Seery V; Gavin MA; Rudensky AY; Atkins MB; Balk SP; Exley MA
Clin Cancer Res; 2007 Apr; 13(7):2100-8. PubMed ID: 17404092
[TBL] [Abstract][Full Text] [Related]
9. Recruitment of immature plasmacytoid dendritic cells (plasmacytoid monocytes) and myeloid dendritic cells in primary cutaneous melanomas.
Vermi W; Bonecchi R; Facchetti F; Bianchi D; Sozzani S; Festa S; Berenzi A; Cella M; Colonna M
J Pathol; 2003 Jun; 200(2):255-68. PubMed ID: 12754747
[TBL] [Abstract][Full Text] [Related]
10. Phase 1 evaluation of intralesionally injected TLR9-agonist PF-3512676 in patients with basal cell carcinoma or metastatic melanoma.
Hofmann MA; Kors C; Audring H; Walden P; Sterry W; Trefzer U
J Immunother; 2008 Jun; 31(5):520-7. PubMed ID: 18463532
[TBL] [Abstract][Full Text] [Related]
11. Feasibility of flowcytometric quantitation of immune effector cell subsets in the sentinel lymph node of the breast after cryopreservation.
van Pul KM; Vuylsteke RJ; Bril H; Stockmann HB; de Gruijl TD
J Immunol Methods; 2012 Jan; 375(1-2):189-95. PubMed ID: 22062586
[TBL] [Abstract][Full Text] [Related]
12. Arming the Melanoma Sentinel Lymph Node through Local Administration of CpG-B and GM-CSF: Recruitment and Activation of BDCA3/CD141(+) Dendritic Cells and Enhanced Cross-Presentation.
Sluijter BJ; van den Hout MF; Koster BD; van Leeuwen PA; Schneiders FL; van de Ven R; Molenkamp BG; Vosslamber S; Verweij CL; van den Tol MP; van den Eertwegh AJ; Scheper RJ; de Gruijl TD
Cancer Immunol Res; 2015 May; 3(5):495-505. PubMed ID: 25633713
[TBL] [Abstract][Full Text] [Related]
13. CpG ODN enhance antigen-specific NKT cell activation via plasmacytoid dendritic cells.
Marschner A; Rothenfusser S; Hornung V; Prell D; Krug A; Kerkmann M; Wellisch D; Poeck H; Greinacher A; Giese T; Endres S; Hartmann G
Eur J Immunol; 2005 Aug; 35(8):2347-57. PubMed ID: 16025562
[TBL] [Abstract][Full Text] [Related]
14. FLT3 ligand administration after hematopoietic cell transplantation increases circulating dendritic cell precursors that can be activated by CpG oligodeoxynucleotides to enhance T-cell and natural killer cell function.
Chen W; Chan AS; Dawson AJ; Liang X; Blazar BR; Miller JS
Biol Blood Marrow Transplant; 2005 Jan; 11(1):23-34. PubMed ID: 15625541
[TBL] [Abstract][Full Text] [Related]
15. Immunosuppressive dendritic and regulatory T cells are upregulated in melanoma patients.
McCarter MD; Baumgartner J; Escobar GA; Richter D; Lewis K; Robinson W; Wilson C; Palmer BE; Gonzalez R
Ann Surg Oncol; 2007 Oct; 14(10):2854-60. PubMed ID: 17593331
[TBL] [Abstract][Full Text] [Related]
16. Immunomodulation of the melanoma sentinel lymph node: a novel adjuvant therapeutic option.
Molenkamp BG; van Leeuwen PA; van den Eertwegh AJ; Sluijter BJ; Scheper RJ; Meijer S; de Gruijl TD
Immunobiology; 2006; 211(6-8):651-61. PubMed ID: 16920504
[TBL] [Abstract][Full Text] [Related]
17. Prediction of nonsentinel lymph node involvement in patients with a positive sentinel lymph node in malignant melanoma.
Page AJ; Carlson GW; Delman KA; Murray D; Hestley A; Cohen C
Am Surg; 2007 Jul; 73(7):674-8; discussion 678-9. PubMed ID: 17674939
[TBL] [Abstract][Full Text] [Related]
18. Factors predictive of nonsentinel lymph node involvement and clinical outcome in melanoma patients with metastatic sentinel lymph node.
Rossi CR; De Salvo GL; Bonandini E; Mocellin S; Foletto M; Pasquali S; Pilati P; Lise M; Nitti D; Rizzo E; Montesco MC
Ann Surg Oncol; 2008 Apr; 15(4):1202-10. PubMed ID: 18165880
[TBL] [Abstract][Full Text] [Related]
19. Limited amounts of dendritic cells migrate into the T-cell area of lymph nodes but have high immune activating potential in melanoma patients.
Verdijk P; Aarntzen EH; Lesterhuis WJ; Boullart AC; Kok E; van Rossum MM; Strijk S; Eijckeler F; Bonenkamp JJ; Jacobs JF; Blokx W; Vankrieken JH; Joosten I; Boerman OC; Oyen WJ; Adema G; Punt CJ; Figdor CG; de Vries IJ
Clin Cancer Res; 2009 Apr; 15(7):2531-40. PubMed ID: 19318472
[TBL] [Abstract][Full Text] [Related]
20. Optimal detection of sentinel lymph node metastases by intraoperative radioactive threshold and molecular analysis in patients with melanoma.
Manca G; Romanini A; Pellegrino D; Borsò E; Rondini M; Orlandini C; Zucchi V; Pasqualetti F; Mariani G
J Nucl Med; 2008 Nov; 49(11):1769-75. PubMed ID: 18927334
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
